Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024
July 01, 2024 05:10 ET
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced certain preliminary, unaudited key...
Alvotech Receives Conversion Notices for Majority of Convertible Bonds
June 26, 2024 04:50 ET
|
Alvotech
REYKJAVIK, Iceland , June 26, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
Eigendur meirihluta breytilegra skuldabréfa Alvotech nýta rétt til að breyta yfir í hlutabréf
June 26, 2024 04:50 ET
|
Alvotech
Alvotech (NASDAQ: ALVO) tilkynnti í dag að eigendur meirihluta breytilegra skuldabréfa félagins sem upphaflega voru útgefin 16. nóvember og 20. desember 2022 með lokagjalddaga 20. desember 2025, hafi...
Alvotech Receives Conversion Notices for Majority of Convertible Bonds
June 26, 2024 04:50 ET
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that holders of the majority of...
Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe
June 18, 2024 04:01 ET
|
Alvotech
Advanz Pharma secures rights to commercialize Alvotech’s biosimilar candidate for Eylea® in Europe Advanz Pharma will leverage its existing specialty and hospital capabilities in Europe to ensure...
Alvotech og Advanz Pharma undirrita samning um markaðssetningu í Evrópu á fyrirhugaðri líftæknilyfjahliðstæðu við Eylea
June 18, 2024 04:00 ET
|
Alvotech
Advanz Pharma fær rétt til markaðssetningar fyrirhugaðrar líftæknilyfjahliðstæðu við Eylea í Evrópu, en Alvotech þróar nú tvær útgáfur lyfsinsAdvanz Pharma mun nýta þekkingu á markaðssetningu...
Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe
June 18, 2024 04:00 ET
|
Alvotech
Advanz Pharma secures rights to commercialize Alvotech’s biosimilar candidate for Eylea® in EuropeAdvanz Pharma will leverage its existing specialty and hospital capabilities in Europe to ensure...
Alvotech and STADA add to strategic alliance through denosumab partnership
June 11, 2024 04:00 ET
|
Alvotech
STADA assumes marketing license for Alvotech’s proposed biosimilar referencing Prolia®/Xgeva® (denosumab) in Europe, including Switzerland and the UK, as well as rights in selected markets in Central...
Alvotech og STADA útvíkka samstarf sitt með nýjum samningi um AVT03, fyrirhugaða hliðstæðu við Prolia og Xgeva
June 11, 2024 04:00 ET
|
Alvotech
Alvotech (NASDAQ: ALVO) og STADA tilkynntu í dag að fyrirtækin hafi útvíkkað samstarf sitt með samningi um markaðssetningu AVT03, fyrirhugaðrar líftæknilyfjahliðstæðu við Prolia og Xgeva (denosumab)...
Alvotech and STADA add to Strategic Alliance through Denosumab Partnership
June 11, 2024 04:00 ET
|
Alvotech
STADA assumes marketing license for Alvotech’s proposed biosimilar referencing Prolia®/Xgeva® (denosumab) in Europe, including Switzerland and the UK, as well as rights in selected markets in Central...